Geistlich Pharma AG, based in Switzerland, is a global leader in regenerative medicine, specializing in the development, production, and distribution of medical devices and drugs. With a history dating back to 1851, the company operates through three business units: Geistlich Biomaterials, Geistlich Surgery, and Geistlich Medical, with a presence in ten subsidiaries and global distribution. The company's 500 employees are dedicated to advancing regenerative dentistry and biological bone and cartilage regeneration.
The company's long-term planning and commitment to innovation are supported by its ownership structure, allowing for continuous investment in research, technology, and the cultivation of specialized talent. Geistlich Pharma AG's dedication to advancement has positioned them as the global market leader in regenerative dentistry and the foremost supplier of drugs and medical devices in selected application areas.
There is no investment information
No recent news or press coverage available for Geistlich.
We care about your data, and we'd love to use cookies make your experience better.
